A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). A multicenter¸open label phase II trial of liposomal doxorubicin (LD) and docetaxel (DX), followed by concurrent chemotherapy and radiation therapy in locally advanced high risk, early breast cancer (HRBC). J Clin Oncol 30: 2012 (ASCO MEETING ABSTRACTS May 30, 2012:e11041 ASCO MEETING ABSTRACTS May 30, 2012:e11041